Gracell Biotechnologies Q2 EPS $(0.30) Beats $(0.37) Estimate
Portfolio Pulse from Benzinga Newsdesk
Gracell Biotechnologies reported Q2 losses of $(0.01) per share, beating the analyst consensus estimate of $(0.37) by 98.38 percent. This is a 98 percent increase over losses of $(0.30) per share from the same period last year.
August 14, 2023 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gracell Biotechnologies reported better than expected Q2 earnings, with losses of $(0.01) per share, significantly beating the analyst consensus estimate of $(0.37).
Gracell Biotechnologies reported a much smaller loss than expected for Q2, which is a positive signal for investors. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100